icon_loop icon_cart icon_arrow-down icon_pick-winners icon_make-better-decisions icon_gofaster-gosmarter icon_equio icon_custom-research icon_conquer-the-wild icon_be-anonymous-and-secure icon_analyst-reports icon_access-realtime-data icon_youtube icon_twitter icon_linkedin icon_facebook
PharmaReport_ProductImg

From Prescription to Recommendation: How Cannabis Could Disrupt the Pharmaceutical Industry

Free!

This will also add the following products to your cart:

  • Equio® Essential Add-on

Category:

Product Description

In our latest study, From Prescription to Recommendation: How Cannabis Could Disrupt the Pharmaceutical Industry, our data analysts have found that if medical cannabis were legalized nationally, pharmaceutical expenditures on the top nine conditions commonly treated by medical cannabis could fall an estimated $18.5 billion between 2016 and 2019.

The study looks at the impact to pharmaceutical sales on the nine ailments most commonly treated with cannabis which are:

  • Chronic Pain
  • Post-Traumatic Stress Disorder (PTSD)
  • Sleep Disorders
  • Anxiety
  • Nerve Pain
  • Chemotherapy Induced Nausea and Vomiting (CINV)
  • Tourette Syndrome
  • Glaucoma
  • Seizures/Epilepsy

Find out what’s next for medical cannabis and the pharmaceutical industry in your FREE copy of our study today!

 

*Published in May 2017

Not the reports you are looking for?

Build your own bundle here.